Clear Creek Financial Management LLC Buys New Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Clear Creek Financial Management LLC bought a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,313 shares of the company’s stock, valued at approximately $81,000.

Other large investors also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC bought a new stake in Recursion Pharmaceuticals during the third quarter valued at approximately $25,000. Farther Finance Advisors LLC grew its position in Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after buying an additional 4,091 shares during the period. GAMMA Investing LLC grew its position in Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after buying an additional 6,036 shares during the period. Amalgamated Bank grew its position in Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after buying an additional 2,459 shares during the period. Finally, San Luis Wealth Advisors LLC bought a new stake in Recursion Pharmaceuticals during the third quarter valued at approximately $69,000. 89.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on RXRX shares. Leerink Partners lowered their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Jefferies Financial Group lowered their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Needham & Company LLC lowered their price target on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, September 4th. Finally, KeyCorp lowered their price target on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Price Performance

RXRX stock opened at $6.64 on Tuesday. Recursion Pharmaceuticals, Inc. has a one year low of $5.03 and a one year high of $15.74. The company’s fifty day moving average price is $6.61 and its 200-day moving average price is $7.64. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07. The company has a market capitalization of $1.87 billion, a PE ratio of -4.10 and a beta of 0.81.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The company had revenue of $14.42 million during the quarter, compared to analysts’ expectations of $11.96 million. During the same period last year, the firm posted ($0.38) EPS. Recursion Pharmaceuticals’s quarterly revenue was up 30.9% compared to the same quarter last year. On average, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other news, COO Tina Marriott sold 6,000 shares of the business’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $7.56, for a total value of $45,360.00. Following the transaction, the chief operating officer now owns 521,138 shares of the company’s stock, valued at approximately $3,939,803.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Christopher Gibson sold 30,000 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $7.10, for a total transaction of $213,000.00. Following the sale, the chief executive officer now owns 758,738 shares of the company’s stock, valued at $5,387,039.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $7.56, for a total transaction of $45,360.00. Following the sale, the chief operating officer now directly owns 521,138 shares in the company, valued at approximately $3,939,803.28. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 201,682 shares of company stock valued at $1,320,868. 15.75% of the stock is currently owned by corporate insiders.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.